The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
Research Funding - Astellas Pharma (Inst)
 
Bin Luo
No Relationships to Disclose
 
Siyuan S Guo
No Relationships to Disclose
 
Todd Knutson
No Relationships to Disclose
 
Jacqueline Lyman
No Relationships to Disclose
 
Anna Kobilka
No Relationships to Disclose
 
Himisha Beltran
Consulting or Advisory Role - AstraZeneca; Bayer; Daicchi Sankyo; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Emmanuel S. Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; Medscape; MJH Life Sciences; NCCN/Pfizer; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Imvax; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
 
William Kevin Kelly
Honoraria - Amgen; Janssen Oncology
Consulting or Advisory Role - Bayer; Janssen Oncology
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Eric J. Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Fortis; Janssen Oncology; Teon Therapeutics
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Arvinas; AstraZeneca; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
Other Relationship - Novartis
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen; Bayer; Janssen Oncology; Novartis
 
Scott M. Dehm
Consulting or Advisory Role - Celgene; Janssen Research & Development; Oncternal Therapeutics
Research Funding - Medivation/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from licensing genome-engineered prostate cancer cell lines
Travel, Accommodations, Expenses - Oncternal Therapeutics
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Epic Sciences; Exelixis; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; ZAlpha
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc